What do systematic reviews say?

All‐cause mortality · adults with growth‐hormone secreting pituitary adenomas

Surgery for recurrent or persistent disease · adults with growth‐hormone secreting pituitary adenomas

Non‐surgical therapy for recurrent or persistent disease · adults with growth‐hormone secreting pituitary adenomas

QoL of participants living with SCD and their caregivers · people with sickle cell disease

Adverse effects · people with sickle cell disease

Frequency of hospitalization · people with sickle cell disease

QoL of participants living with SCD and their caregivers · sickle cell disease

Frequency of sickle cell‐related complications · sickle cell disease

Frequency of crisis · sickle cell disease

QoL of participants living with SCD and their caregivers · adults with sickle cell disease (adults with homozygous SCA or sickle beta 0 thalassaemia SCD)

Severity of pain · sickle cell disease

QoL of participants living with SCD and their caregivers · sickle cell disease

Frequency of hospitalization · sickle cell disease

Frequency of sickle cell‐related complications · sickle cell disease

Frequency of hospitalization · adults with sickle cell disease (adults with homozygous SCA or sickle beta 0 thalassaemia SCD)

Severity of pain · people with sickle cell disease

Functional disability at 3 months ‐ not measured · adults experiencing acute traumatic stress symptoms

Quality of life at 3 months ‐ not measured · adults experiencing acute traumatic stress symptoms

Functional disability at 3 months ‐ not measured · adults experiencing acute traumatic stress symptoms

Proportion of people with ≥ 1 serious adverse events during treatment · participants with unresectable hepatocellular carcinoma